Featured image: A laboratory microscope illustrates organoid research. Contextual photograph; not the smoke-exposure system, a lung organoid or a tumour sample. Photo: Ousa Chea / Unsplash. Unsplash licence.
Cancer is often described as a disease of mutations. A new lung study sharpens that picture: the condition of a cell before a mutation arrives may help decide whether that mutation can start a tumour and what kind of tumour emerges.
In a PNAS paper published on 5 October 2026, researchers exposed laboratory-grown lung organoids to cigarette-smoke condensate for as long as six months. Smoke reshaped stem-cell states through epigenetic and gene-activity changes. When the team later added KRAS activation or removed TP53, different cell populations produced different forms of non-small cell lung cancer after implantation in mice. This was organoid and animal research, not a human trial.
Organoids let researchers watch a slow transformation
Organoids are small three-dimensional models grown from tissue. They reproduce selected cell types and interactions without recreating an entire lung. The main experiments began with normal mouse lung tissue; the researchers confirmed key early observations in organoids made from normal human lung tissue.
Over months of smoke exposure, the balance of cell populations changed. DNA methylation and chromatin accessibility also shifted. Methylation adds chemical marks associated with gene regulation, while chromatin accessibility reflects how easily cellular machinery can reach particular DNA regions. Neither process necessarily changes the DNA sequence itself.
The exposed organoids increasingly adopted tumour-permissive states. Inflammatory signalling and programmed-cell-death pathways weakened, including activity around ZBP1, a regulator that can help trigger inflammatory cell death. That pattern could let damaged cells survive circumstances in which they would otherwise be removed.
KRAS and TP53 selected different starting cells
The team introduced either mutant KRAS, a growth-promoting oncogene, or loss of TP53, a tumour-suppressor gene. It then implanted cells from exposed and unexposed organoids into mice. Johns Hopkins reports that tumours formed only from smoke-exposed organoids carrying one of those alterations in this experimental system.
KRAS primarily drove adenocarcinoma-like tumours from a state derived from bronchioalveolar stem cells, found near the junction of airways and air sacs. TP53 loss produced squamous-cell-carcinoma features from a state derived from basal cells that maintain airway lining. The driver was not deliberately placed into one chosen cell type; the altered environment appeared to let each mutation favour a different state.
Smoke exposure without the engineered driver did not produce tumours, and the drivers in unexposed control organoids did not do so either. That result supports an interaction between exposure-shaped cell state and mutation in this model. It does not mean the same two-step sequence is required in every human lung cancer.
The study maps risk biology, not a prevention test
The researchers also found lower ZBP1 and related interferon-pathway expression in human lung-adenocarcinoma data when KRAS mutations were present, lending clinical relevance to the model. Database associations, however, cannot prove that smoke-induced ZBP1 suppression caused a person’s tumour.
Organoids lack the full immune, vascular and mechanical environment of a living lung. Cigarette-smoke condensate is a controlled proxy for inhaled smoke, not an exact recreation of dose and exposure in people. Implanting engineered cells into mice tests tumour-forming potential under artificial conditions.
The experiment also does not estimate how long a similar state persists after smoke exposure ends. Human lungs encounter changing doses, infections and repair cycles over decades. Sampling people before cancer develops would be necessary to learn whether the proposed states identify future risk rather than only explaining tumours retrospectively.
The work may eventually help identify molecular warning signs or vulnerabilities that differ between KRAS- and TP53-related disease. Any biomarker would need prospective validation, and any intervention would require separate safety and efficacy studies.
For now, the study’s contribution is mechanistic. It shows how long-term exposure can reprogramme the cellular ground on which mutations act. That is more informative than saying smoke simply “causes mutations,” but it does not create a clinical test or treatment—and it does not reduce the established importance of avoiding tobacco smoke.
Reporting and source checks completed on 13 October 2026. By FutureTechDose Editor.
Leave a Reply